Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S
{"title":"胰岛素受体底物 1（insulin receptor substrate 1，IRS 1）表达与头颈部鳞状细胞癌预后的关系--系统综述和荟萃分析。","authors":"Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S","doi":"10.1159/000541004","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.</p><p><strong>Methods: </strong>A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.</p><p><strong>Results: </strong>A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.</p><p><strong>Conclusion: </strong>This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASSOCIATION OF INSULIN RECEPTOR SUBSTRATE 1 (IRS 1) EXPRESSION IN THE PROGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - A SYSTEMATIC REVIEW AND META ANALYSIS.\",\"authors\":\"Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S\",\"doi\":\"10.1159/000541004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.</p><p><strong>Methods: </strong>A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.</p><p><strong>Results: </strong>A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.</p><p><strong>Conclusion: </strong>This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541004\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
ASSOCIATION OF INSULIN RECEPTOR SUBSTRATE 1 (IRS 1) EXPRESSION IN THE PROGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - A SYSTEMATIC REVIEW AND META ANALYSIS.
Introduction: Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.
Methods: A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.
Results: A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.
Conclusion: This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
